Amylyx Pharmaceuticals

We are a clinical-stage pharmaceutical company based in Cambridge, Massachusetts. We develop novel therapies for diseases with high unmet medical needs, focusing our scientific efforts where we can make a significant impact. Josh Cohen and Justin Klee co-founded Amylyx in 2013, and we went public on NASDAQ ($AMLX) in January 2022.

Our pipeline includes several therapies under investigation:

• Avexitide, a GLP-1 receptor antagonist, is ready for Phase 3 and has FDA Breakthrough Therapy designation. It’s in clinical trials for post-bariatric hypoglycemia (PBH), with the Phase 3 LUCIDITY trial starting in April 2025, and for congenital hyperinsulinism (HI).
• AMX0035 is a combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO). We are investigating this therapy for Wolfram syndrome; positive interim data from the Phase 2 HELIOS trial came out in April 2024, followed by positive topline data in October 2024. AMX0035 has Orphan Drug Designation from both the FDA and the European Commission for Wolfram syndrome. It was previously approved for amyotrophic lateral sclerosis (ALS) in Canada (ALBRIOZA™) in June 2022 and in the U.S. (RELYVRIO®) in September 2022. However, we are voluntarily discontinuing marketing for ALBRIOZA and RELYVRIO as of March-April 2024 after the Phase 3 PHOENIX trial did not meet its primary endpoint. Exploratory analysis from the Phase 2 PEGASUS trial also showed early evidence that AMX0035 affects multiple pathways related to neurodegeneration, including tau, in Alzheimer’s disease.
• AMX0114 is in development for amyotrophic lateral sclerosis (ALS). The Phase 1 LUMINA clinical trial starts in April 2025. The FDA granted AMX0114 Fast Track designation for ALS in May 2025.

Our mission is to develop novel therapies for diseases with high unmet medical needs. We pursue opportunities with urgency, rigorous science, and commitment, exploring scientific approaches where we can make the greatest difference.

We are guided by our core values, which we call “Rooted in Connection”:

• We are audacious: We envision new possibilities, boldly seek new approaches, and innovate for people living with serious diseases.
• We are curious: We ask questions, listen, learn, and improve continuously by sharing knowledge.
• We are authentic: We are honest and transparent in all our actions, taking responsibility for the communities we serve and our colleagues.
• We are engaged: We connect deeply with community members and their care providers to understand their needs and experiences.
• We are accountable: We prioritize people living with high unmet medical needs and act urgently on their behalf.

Amylyx Pharmaceuticals has a team of 51-200 employees. The company’s culture, “Rooted in Connection,” focuses on its ties to the communities it serves, and how it connects questions to solutions and insights to action. The work environment values collaboration, innovation, and integrity. It is supportive, inclusive, and led by transparent leadership.

Amylyx attracts determined, passionate, and empathetic individuals. Employees are encouraged to grow, take initiative, and make an impact, working closely together. The culture is patient-centric, with a blend of rigorous science and transparent leadership. The company operates in a hybrid-remote model with its headquarters in Cambridge, MA. Some roles and company events require occasional office travel.

We offer a comprehensive benefits package that includes medical, dental, and vision insurance, along with tax-advantaged accounts like Flexible Spending Accounts (FSA), Health Savings Accounts (HSA), Dependent Care FSA, and Limited Purpose FSA for eligible expenses.

Our additional benefits include:

• An agile, hybrid-remote work environment, with our headquarters in Cambridge, MA.
• Three annual company-wide in-person “Anchor Weeks” and bi-weekly “Amylyx Exchange” meetings.
• A Learning and Development Program to help you grow your skills.
• A Recognition Platform for peer and leadership acknowledgment.
• Flexible Paid Time Off for vacation, personal needs, and appointments.
• Financial wellbeing support, including a 5% 401(k) employer contribution.
• An Employee Assistance Program that offers mental health support, work-life solutions, financial resources, and legal guidance.
• Paid Parental Leave.
• Monthly mobile phone reimbursement.
• Competitive compensation.
• Remote work opportunities within the United States.
• Accommodations for candidates during the selection process.
• Travel opportunities, including occasional trips to the Cambridge, MA office and other company events, as related to your role.